Last reviewed · How we verify
low sodium diet
low sodium diet is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 1 development.
A low sodium diet is a dietary approach that restricts daily sodium intake to 1,500 to 2,400 milligrams. This diet has been studied in various clinical trials for conditions such as hypertension, obesity, and long COVID-19 syndrome, often in conjunction with other interventions like sodium phosphate or sevelamer.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | low sodium diet |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Effect of the DASH Diet on Clinical and Metabolic Parameters in Children With MASLD (NA)
- Can Changes in Dialysate Sodium Concentration Improve Blood Pressure and Endothelial Function in Chronic HD Patients? (NA)
- The Impact of Low Sodium Salt Substitute Use on Serum Potassium Levels Among Patients With Hypertension (NA)
- Genetic Architecture of Natriuretic Peptides and Blood Pressure Response (NA)
- Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure (PHASE4)
- Mechanisms Underlying the Protective Vascular Effects of Dietary Potassium in Humans (NA)
- Mi Propio Camino Intervention RCT for Blood Pressure Medication Adherence (NA)
- Stimulating Amyloid Clearance in Cerebral Amyloid Angiopathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low sodium diet CI brief — competitive landscape report
- low sodium diet updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about low sodium diet
What is low sodium diet?
Who makes low sodium diet?
What development phase is low sodium diet in?
Related
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing